Preclinical and Clinical Evaluation of Once-Daily Aminoglycoside Chemotherapy

REFERENCES

• Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39 (3): 650–655.
   PubMed Web of Science ®Google Scholar
• Ebert SC, Craig WA. Pharmacodynamic properties of antibiotic: application to drug monitoring and dosage regi-men design. Infect Control Hosp Epidemiol 1990; 11: 319–326.
   PubMed Web of Science ®Google Scholar
• Drusano GL. Role of pharmacokinetics in the outcome of infections - Minireview. Antimicrob Agents Chemother 1988; 32 (3): 289–297.
   PubMed Web of Science ®Google Scholar
• Begg EJ, Peddie BA, Chambers ST, et al. Comparison of gentamicin dosing regimens using an in-vitro model. J Antimicrob Chemother 1992; 29: 427–433.
   PubMed Web of Science ®Google Scholar
• Davis BD. Mechanism of the bactericidal action of aminoglycosides. Microbiol Rev 1987; 57: 341–350.
   Google Scholar
• Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak con-centration to minimum inhibitory concentration. J Infect Dis 1987; 155: 93–99.
   PubMed Web of Science ®Google Scholar
• Periti P, Novelli A. Antibiotici aminoglucosidici. Antibioticoterapia Pratica 1988; 1: 87–98.
   Google Scholar
• Tulkens PM, Laurenti G. Mechanisms of aminoglyco-side-induced nephrotoxicity: a review of experimental studies in animals with gentamicin and four other aminoglycosides (amikacin, tobramycin, netilmicin and dibekacin) at low doses. Chemioterapia 1984; Suppl 5: 60-71.
   Google Scholar
• Giuliano RA, Verpooten GA, Verbist L, et al. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986; 236: 470–475.
   PubMed Web of Science ®Google Scholar
• Giuliano RA, Verpooten GA, DeBroe ME. The effect of dosing strategy on kidney cortical accumulation of amino-glycosides in rats. Am J Kidney Dis 1986; 8: 297–303.
   PubMed Web of Science ®Google Scholar
• Tran Ba Huy P, Deffrennes D. Aminoglycoside ototox-icity: influence of dosage regimen on drug uptake and corre-lation between membrane binding and some clinical features. Acta Otolaryngol 1988; 105: 511–515.
   Google Scholar
• Edson RS, Terrell CL. The aminoglycosides: strepto-mycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin and sisomicin. Mayo Clin Proc 1987; 62: 916–920.
   PubMed Web of Science ®Google Scholar
• Chan GLC. Alternative dosing strategy for aminoglyco-sides: impact on efficacy, nephrotoxicity, and ototoxicity. DICP, Ann Pharmacother 1989; 23: 788–794.
   PubMedGoogle Scholar
• Powell SH, Thompson WL, Luthe MA, et al. Once daily vs. continuous aminoglycoside dosing: efficacy and toxi-city in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983; 147: 918–932.
   Google Scholar
• Prins JM, Biiller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335–339.
   PubMed Web of Science ®Google Scholar
• Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia. Am J Med 1984; 77: 657–662.
   PubMed Web of Science ®Google Scholar
• Mattie H, Craig WA, Pechere JC. Determinants of effi-cacy and toxicity of aminoglycosides - Review. J Antimicrob Chemother 1989; 24: 281–293.
   PubMed Web of Science ®Google Scholar
• Pechere J-C, Craig WA, Meunier F. Once daily dosing of aminoglycoside: one step forward. J Antimicrob Chemother 1991; 27 (Suppl C): 149-152.
   Google Scholar
• Hustinx WNM, Hoepelmam IM. Aminoglycoside dosage regimens. Is once a day enough? Clin Pharmacokinet 1993; 25 (6): 427–432.
   PubMed Web of Science ®Google Scholar
• Ellis-Pegler RB, Chambers S, Begg EJ, Barclay ML. Aminoglycoside dosing: time to change - Editorial. Aust NZ J Med 1994; 24: 359–361.
   PubMedGoogle Scholar
• Gerber AU, Wiprachtiger P, Stettler-Spichiger U, Lebex G. Constant infusions vs. intermittent doses of gentam-icin against Pseudomonas aeruginosa in vitro. J Infect Dis 1982; 145: 554–560.
   Google Scholar
• Blaser J, Stone BB, Zinner SH. Efficacy of intermittent versus continuous administration of netilmicin in a two-com-partment in vitro model. Antimicrob Agents Chemother 1985; 27: 343–349.
   PubMed Web of Science ®Google Scholar
• Dudley MN, Zinner SH. Single daily dosing of amikacin in an in-vitro model. J Antimicrob Chemother 1991; 27 Suppl C: 15-19.
   Google Scholar
• Blaser J. Efficacy of once- and thrice-daily dosing of aminoglycosides in in-vitro models of infection. J Antimicrob Chemother 1991; 27 Suppl C: 21-28.
   Google Scholar
• Craig WA, Vogelman BS. Postantibiotic effects. Ann Intern Med 1987; 106: 900–902.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Craig WA. Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides. Clin Pharmacokinet 1994; 27 (5): 377–392.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Hoban DJ, Harding GKM. The postan-tibiotic effect: a review of in vitro and in vivo data. DICP, Ann Pharmacother 1991; 25: 153–163.
   PubMedGoogle Scholar
• Zhanel GG, Crampton J, Kim S, Nicolle LE, Davidson RJ, Hoban DJ. Antimicrobial activity of subinhibitory con-centrations of ciprofloxacin against Pseudomonas aeruginosa as determined by the killing curve method and the postantibi-otic effect. Chemotherapy 1992; 38: 388–394.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Zhanel GG, Davidson RJ, et al. Postantibiotic effect in Pseudomonas aeruginosa following sin-gle and multiple aminoglycoside exposures in vitro. J Antimicrob Chemother 1994; 33: 937–947.
   PubMed Web of Science ®Google Scholar
• Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Post-antibiotic suppression of bacterial growth. Rev Infect Dis 1981; 3: 28–37.
   PubMedGoogle Scholar
• Isaksson B, Nilsson L, Mailer R, Soren L. Postantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method. J Antimicrob Chemother 1988; 22: 23–33.
   PubMed Web of Science ®Google Scholar
• Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande MA. Single large daily dosing versus intermittent dosing of tobramycin in experimental pseudomonas penumo-nia. J Infect Dis 1988; 158: 7–12.
   PubMed Web of Science ®Google Scholar
• Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986; 108: 835–840.
   PubMed Web of Science ®Google Scholar
• Craig WA, Gudmundsson S. The postantibiotic effect. In: Lorian V, Ed. Antibiotics in Laboratory Medicine. 3rd ed. Baltimore: Williams & Wilkins; 1991: 403–431.
   Google Scholar
• Kumar A, Hay MB, Maier GA, et al. Post-antibiotic effect of ceftazidime, ciprofloxin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia. J Antimicrob Chemother 1992; 30: 597–602.
   PubMed Web of Science ®Google Scholar
• Rescott DL, Nix DE, Holden P, et al. Comparison of two methods for determining in vitro postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988; 157: 287–298.
   PubMedGoogle Scholar
• Rescott DL, Nix DE, Holden P, et al. Comparison of two methods for determining in vitro postantibiotic effects of three antibiotics on Escherichia coli. Antimicrob Agents Chemother 1988; 32: 450–453.
   PubMed Web of Science ®Google Scholar
• Vogelman B, Gudmundsson S, Tumidge J, Leggett J, Craig WA. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988; 157: 287–298.
   PubMed Web of Science ®Google Scholar
• Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharma-codynamic model to determine importance of ratio of antibi-otic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31 (7): 1054–1060.
   PubMed Web of Science ®Google Scholar
• Drusano GL. Human pharmacokinetics of beta-lac-tams, aminoglycosides and their combination. Scand J Infect Dis 1991; 74: 235–248.
   Google Scholar
• Karlowsky JA, Zhanel GG, Kavidson RJ, Hoban DJ. Ance-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994; 38 (5): 1165–1168.
   PubMed Web of Science ®Google Scholar
• Jackson GG, Lolans VT, Daikos GL. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis 1990; 162: 408–413.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Jackson GG, Lolans VT, Livermore DM. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 1990; 162: 414–420.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycosides in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991; 35: 117–123.
   PubMed Web of Science ®Google Scholar
• Barclay ML, Begg EJ, Chambers ST. Adaptive resis-tance following single doses of gentamicin in a dynamic in vitro model. Antimicrob Agents Chemother 1992; 36: 1951–1957.
   PubMed Web of Science ®Google Scholar
• Barclay ML, Begg EJ, Hickling KG. What is the evi-dence for once-daily aminoglycoside therapy? Clin Pharmacokinet 1994; 27 (1): 32–48.
   PubMed Web of Science ®Google Scholar
• Gilleland LB, Gilleland HE, Gibson JA, et al. Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa. J Med Microbiol 1989; 29 (1): 41–50.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Karlowsky JA, Hoban DJ, Davidson RJ. Antimicrobial activity of subinhibitory concentrations of aminoglycosides against Pseudomonas aeruginosa as deter-mined by the killing-curve method and the postantibiotic effect. Chemotherapy 1991; 37: 114–121.
   PubMed Web of Science ®Google Scholar
• Nordstrom L, Ringberg H, Cronberg S, Tjemstrom O, Walder M. Does administration of an aminoglycoside in a sin-gle daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990; 25: 159–173.
   PubMed Web of Science ®Google Scholar
• Periti P, Novelli A, Grassi C, Meli E, Melani A, Mazzei T and Other Participants in the Italian Cooperative Study Group. Once-daily compared with twice-daily administration of netilmicin in the treatment of respiratory tract infectious disease. J Chemother 1991; Suppl 4: 323-325.
   Google Scholar
• Bergeron MG. What predinical data are needed to jus-tify once-daily therapy? J Clin Pharmacol 1992; 32: 698–705.
   PubMed Web of Science ®Google Scholar
• Gilbert DN. Once-daily aminoglycoside therapy - Minireview. Antimicrob Agents Chemother 1991; 35 (3): 399–405.
   PubMed Web of Science ®Google Scholar
• Bennett WM, Wood CW, Houghton DC, Gilbert N. Modification of experimental aminoglycoside nephrotoxicity. Am J Kidney Dis 1986; 3: 292–296.
   Google Scholar
• Luft FC, Bennett WM, Gilbert DN. Experimental aminoglycoside nephrotoxicity: accomplishments and future potential. Rev Infect Dis 1983; 5 (Suppl): S268-S293.
   Google Scholar
• Patel G, Chau NP, Pangon B, Fantin B, Vallois JM, Faurisson F, Carbon C. Single daily dosing of antibiotics: importance of in vitro killing rate, serum half-life and protein binding. Antimicrob Agents Chemother 1991; 35: 2085–2090.
   PubMed Web of Science ®Google Scholar
• Patel G, Caillon J, Fautin B, et al. Impact of dosage schedule on the efficacy of gentamicin, tobramycin or amikacin in an experimental model of Serratia marcescens endocarditis. In vitro and in vivo correlation. Antimicrob Agents Chemother 1991; 25: 111–116.
   Google Scholar
• Fantin B, Ebert S, Leggett J, et al. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against Gram-negative bacilli. J Antimicrob Chemother 1991; 27: 829–836.
   PubMed Web of Science ®Google Scholar
• Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991; 27 Suppl C: 29-40.
   Google Scholar
• Gerber AU. Comparison of once-daily versus thrice-daily human equivalent dosing of aminoglycosides: basic con-siderations and experimental approach. J Drug Dev 1988; 1 (Suppl 3): 17–23.
   Google Scholar
• Gerber AU, Kozak S, Segessnmann C, et al. Once-daily versus thrice-daily administration of netilmicin in combina-tion therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model. Eur J Clin Microbiol Infect Dis 1989; 8 (3): 233–237.
   PubMed Web of Science ®Google Scholar
• Gerber AU, Stritzko T, Segessnmann C, et al. Simulation of human pharmacokinetic profiles in mice, and impact on antimicrobial efficacy of netilmicin, ticarcillin and ceftazidime in the peritonitis-septicaemia model. Scand J Infect Dis 1990; 74: 195–203.
   Google Scholar
• Herscovici LG, Grise G, Thauvin C, Lemeland JF, Fillastre JP. Efficacy and safety of once daily versus intermit-tent dosing of tobramycin in rabbits with acute pyelonephro-tis. Scand J Infect Dis 1988; 20: 205–212.
   PubMed Web of Science ®Google Scholar
• Wood CA, Norton DR, Kohlepp PW, et al. The influ-ence of tobramycin dosage regimen on nephrotoxicity and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 1988; 158: 13–22.
   PubMed Web of Science ®Google Scholar
• Vogelman B, Gudmundsson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831–847.
   PubMed Web of Science ®Google Scholar
• Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 281–292.
   PubMed Web of Science ®Google Scholar
• McDonald PJ, Wetherall BL, Pruul H. Postantibiotic leucocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 1981; 3: 38–44.
   PubMedGoogle Scholar
• Luft FC, Bloch R, Sloan RS, et al. Comparative nephro-toxicity of aminoglycoside antibiotics in rats. J Infect Dis 1978; 138: 541–545.
   PubMed Web of Science ®Google Scholar
• Olier B, Viotte G, Morin JP, et al. Influence of dosage regimen on experimental tobramycin nephrotoxicity. Chemotherapy 1983; 29: 385–394.
   PubMed Web of Science ®Google Scholar
• Frame PT; Phair JP, Watanakunakorn C, Bannister TWP. Pharmacological factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis 1977; 135: 952–956.
   PubMed Web of Science ®Google Scholar
• Reiner NE, Bloxham DD, Thompson WL. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemther 1978; 4 Suppl A: 85-101.
   Google Scholar
• Bennett WM, Plamp CE, Gilbert DN, et al. The influ-ence of dosage regimen on experimental gentamicin nephro-toxicity: Dissociation of peak serum levels from renal failure. J Infect Dis 1979; 140: 576–580.
   PubMed Web of Science ®Google Scholar
• Brownell WE, Bader CR, Bertrand D, et al. Evoked mechanical responses of isolated cochlear outer hair cells. Science 1985; 1227: 194–196.
   Google Scholar
• Zenner HP, Zimmermann U, Schmitt U. Reversible contraction of isolated mammalian cochlear hair cells. Hear Res 1985; 18: 127–133.
   PubMed Web of Science ®Google Scholar
• Hayashida T, Nomura Y, Iwamori M, et al. Distribution of gentamicin by immunofluorescence in the guinea pig inner ear. Arch otorhinolaryngology 1985; 242: 257–264.
   PubMedGoogle Scholar
• Aran JM, Dulon D, Erre JP, et al. Evidence that gen-tamicin acts directly on the hair cells of the cochlea. A phys-iopathological immunohistochemical and radioautographic study in the guinea pig. J Physiol 1988; 406: 58.
   Google Scholar
• Tran Ba Huy P, Bernard P, Schact J. Kinetics of gen-tamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest 1986; 77: 1492–1500.
   Google Scholar
• Bamonte F, Dionisotti S, Gambia M, et al. Relation of dosing regimen to aminoglycoside ototoxicity: evaluation of auditory damage in the guinea pig. Chemotherapy 1990; 36: 41–50.
   PubMed Web of Science ®Google Scholar
• Brummett RE, Fox KE, Bendrick TW, et al. Ototoxicity of tobramycin, gentamicin, amikacin, and sisomicin in the guinea pig. J Antimicrob Chemother 1978; 4 Suppl A: 73-84.
   Google Scholar
• Aran JM, Erre JP, Guilhaume A, et al. The compara-tive ototoxicities of gentamicin, tobramycin and dibekacin in the guinea pig. A functional and morphological cochlear and vestibular study. Acta Otolaryngol 1982; 390 (Suppl): 1-30.
   Google Scholar
• Davis RR, Brummett RE, Bendrick TW, et al. Dissociation of maximum concentration of kanamycin in plas-ma and perilymph from ototoxic effect. J Antimicrob Chemother 1984; 14: 291–302.
   PubMed Web of Science ®Google Scholar
• Takumida M, Nishida I, Nikaido M, et al. Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin. ORL: J Otorhinolaryngol Its Related Specialities 1990; 52: 341–349.
   PubMed Web of Science ®Google Scholar
• Verpooten GA, Giuliano RA, Verbist L, Estermans G, de Broe ME. Once daily dosing decreases renal accumulation of gentamicin and netilmicin. Chin Pharmacol Ther 1989; 45: 22–27.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hoepelman IM, Verhoef F. Once-daily aminoglycoside administration: new strategies for an old drug. Eur J Clin Microbiol Infect Dis 1989; 8: 761–769.
   PubMed Web of Science ®Google Scholar
• Rozdzinski E, Kern WV, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy for febrile neu-tropenic patients. J Antimicrob Chemother 1993; 31: 585–598.
   PubMed Web of Science ®Google Scholar
• Prins JM, Biiller ITR, Kuijper EJ, Tange RA, Speelman P. Once-daily gentamicin versus once-daily netilmicin in pa-tients with serious infections - a randomized clinical trial. J Antimicrob Chemother 1994; 33: 823–835.
   PubMed Web of Science ®Google Scholar
• Raz R, Adawi M, Romano S. Intravenous administra-tion of gentamicin once daily versus thrice daily in adults. Eur J Clin Microbiol Infect Dis 1995; 14: 88–91.
   PubMed Web of Science ®Google Scholar
• Craig WA. Post-antibiotic effects in experimental infec-tion models: relationship to in-vitro phenomena and to treat-ment of infections in man. J Antimicrob Chemother 1993; 31 (Suppl D): 149-158.
   Google Scholar
• Nordstrom L, Lerner SA. Single daily dose therapy with aminoglycosides. J Hosp Infec 1991; 18: 117–129.
   PubMed Web of Science ®Google Scholar
• Parker SE, Davey PG. Practicalities of once-daily aminoglycoside dosing. J Antimicrob Chemother 1993; 31: 4–8.
   PubMed Web of Science ®Google Scholar
• Kumana CR, Yuen KY. Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs 1994; 47 (6): 902–913.
   Google Scholar
• Rodman DP, Maxwell AJ, McKnight T. Extended dosage intervals for aminoglycosides. Am J Hosp Pharm 1994; 51: 2016–2021.
   PubMedGoogle Scholar
• Cronberg S. Antimicrobial practice. Simplified moni-toring of aminoglycosides. J Antimicrob Chemother 1994; 34: 819–827.
   PubMed Web of Science ®Google Scholar
• Jackson SHD, Jamieson MJ, Johnston A, Shepherd AMM. The analysis of dose-response curves - a practical approach. Br J Chin Pharmacol 1987; 23: 199–205.
   PubMed Web of Science ®Google Scholar
• MacArthur RD, Lolans V, Zar F, Jackson GG. Biphasic, concentration-dependent and rate-limited, concen-tration-independent bacterial killing by an aminoglycoside antibiotic. J Infect Dis 1984; 150: 778–790.
   PubMed Web of Science ®Google Scholar
• Bryan LE. Mechanisms of action of aminoglycoside antibiotics. In: Rott RK and Sande MA ( Eds), New Dimensions in Antimicrobial Therapy. Churchill Livingstone, New York, 1984: 17-36.
   Google Scholar
• Hancock REW, Bellido F. Antibiotic uptake: unusual results for unusual molecules. J Antimicrob Chemother 1992; 29: 235–243.
   PubMed Web of Science ®Google Scholar
• Staneva M, Markova B, Atanasova I, Terziivanov D. Pharmacokinetic and pharmacodynamic approach for com-paring two therapeutic regimens using amikacin. Antimicrob Agents Chemother 1994; 38 (5): 981–985.
   PubMed Web of Science ®Google Scholar
• Maller R, Ahrne H, Holmen C, et al. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic Gram-negative infections. Scandinavian Amikacin Once Daily Study Group. J Antimicrob Chemother 1993; 31: 939–948.
   Web of Science ®Google Scholar
• Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with Gram-negative bacteriemia. J Infect Dis 1984; 149: 443–448.
   PubMed Web of Science ®Google Scholar
• Govaerts PJ, Claes J, Van De Heyning PH, Jorens Ph G, Marquet J, De Broe ME. Aminoglycoside-induced ototoxi-city. Toxical Letters 1990; 52: 227–251.
   PubMed Web of Science ®Google Scholar
• Montie T, Patamasucon P. Aminoglycosides: the com-plex problem of antibiotic mechanisms and clinical applica-tions. Eur J Chin Microbiol Infect Dis 1995; 14: 85–87.
   PubMed Web of Science ®Google Scholar
• Townsend PL, Fink MP, Stein KL, Murphy SG. Aminoglycoside pharmacokinetics; dosage requirements and nephrotoxicity in trauma patients. Grit Care Med 1989; 17: 154–157.
   PubMed Web of Science ®Google Scholar
• Marik PE, Havlik I, Monteagudo FSE, Lipman J. The pharmacokinetics of amikacin in critically ill adult and paedi-atric patients: comparison of once- versus twice-daily dosing regimen. J Antimicrob Chemother 1991; 27 (Suppl C): 81-89.
   Google Scholar
• Gatel JM, Ferran F, Araujo V, et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 1987; 31: 1383–1387.
   PubMed Web of Science ®Google Scholar
• Kalmeter G, Dahlager JI. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984; 13: 9–22.
   Web of Science ®Google Scholar
• Noone P, Rogers BT. Pneumonia caused by coliforms and Pseudomonas aeruginosa. J Chin Pathol 1976; 29: 652–656.
   PubMed Web of Science ®Google Scholar
• Li SC, Ioannides-Demos LL, Spicer WJ, et al. Prospective audit of aminoglycoside usage in a general hospi-tal with assessment of clinical processes and adverse clinical outcomes. Med J Australia 1989; 151: 224–232.
   PubMed Web of Science ®Google Scholar
• Reyes MP, Brown WJ, Lerner AM. Treatment of pa-tients with Pseudomonas endocarditis with high dose amino-glycoside and carbenicillin therapy. Medicine 1978; 57: 57–67.
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Boike SC, Levine DP, Erickson SR. Clinical use and toxicity of high-dose tobramycin in patients with pseudomonal endocarditis. J Antimicrob Chemother 1986; 17: 115–120.
   PubMed Web of Science ®Google Scholar
• Tablano O, Reyes M, Rintelmann WF, Lerner AM. Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in Pseudomonas endocardi-tis. J Infect Dis 1984; 149: 257–263.
   PubMed Web of Science ®Google Scholar
• Fraser GL, Valenti AJ, Grimes GR, Corbin RP. Evaluation of high-dose tobramycin-carbenicillin therapy in pseudomonal infections in cystic fibrosis. Drug Intell Clin Pharm 1985; 19: 757–761.
   PubMedGoogle Scholar
• Ter Braak EW, De Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycoside plus β-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin and ceftriaxone. Am J Med 1990; 89: 58–66.
   PubMed Web of Science ®Google Scholar
• Fauvelle F, Perrin P, Belfayol L, et al. Fever and asso-ciated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokinetics. Antimicrob Agents Chemother 1994; 38: 620–623.
   PubMed Web of Science ®Google Scholar
• Blaser J, König C, Simmen H-P, Thurnheer U. Monitoring serum concentrations for once-daily netilmicin dosing regimens - Antimicrobial practice. J Antimicrob Chemother 1994; 33: 341–348.
   PubMed Web of Science ®Google Scholar
• Tulkens PM. Pharmacokinetic and toxicological evalu-ation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother 1991; 27 (Suppl C): 49-61.
   Google Scholar
• McLean AJ, Bastone EB, Ioannides-Demos LL, Spicer WJ. Bactericidal effect of gentamicin trough concentration provides a rationale for administration of bolus doses and maintenance of trough levels. J Antimicrob Chemother 1994; 33: 999–1004.
   PubMed Web of Science ®Google Scholar
• Lebel M, Spino M. Pulse dosing versus continuous infusion of antibiotics: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 1988; 14: 71–95.
   PubMed Web of Science ®Google Scholar
• Bastone EB, Li SC, Ioannides-Demos LL, Spicer WJ, McLean AJ. Kill kinetics and regrowth patterns of E. coli exposed to gentamicin concentration-time profiles simulating in vivo bolus or infusion dosing. Antimicrob Agents Chemother 1993; 37: 914–917.
   PubMedGoogle Scholar
• McLean AJ, Ioannides-Demos LL, Li SC, Bastone EB, Spicer WJ. Bactericidal effect of gentamicin peak concentra-tion provides a rationale for administration of bolus doses. J Antimicrob Chemother 1993; 32: 301–305.
   PubMed Web of Science ®Google Scholar
• Horrevorts AM, Driessen O. de Vitte O, Michal MF, Kerrebijn FF. Dosing of tobramycin in children with cystic fibrosis using serum concentration: II pharmacodynamics. Pharmaceutisch Weekblad (Scientific Edition) 1986; 8: 311.
   Google Scholar
• Prandota J. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs 1988; 35: 542–578.
   PubMed Web of Science ®Google Scholar
• Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, Eds. Applied Pharmacokinetics: principles of Therapeutic Drug Monitoring. Applied Therapeutics Spokane, W.A., 1986: 331-381.
   Google Scholar
• Shevchuk YM, Taylor DM. Aminoglycoside volume of distribution in paediatric patients. Paediatrics 1990; 24: 273–276.
   Google Scholar
• Donati L, Periti P. Antibiotic treatment of burn patients: an Italian multicenter study. Proceedings of the Congress of “Infection in the I.C.U.; Current Problems”, Prague 12-14 November 1993. Int Care Med 1994; 20 (Suppl 4): S30-S34.
   Google Scholar
• MacGowan AP, Reeves DS. Serum monitoring and praticalities of once-daily aminoglycoside dosing. J Antimicrob Chemother 1994; 33: 349–350.
   PubMed Web of Science ®Google Scholar
• Wenk W, Vozeh S, Follath F. Serum level monitoring of antibacterial drugs: a review. Clin Pharmacokinet 1984; 9: 475–492.
   PubMed Web of Science ®Google Scholar
• Novelli A, Cassetta MI, Dami A, et al. Valutazione far-macocinetica della tobramicina dopo somministrazione i.m. di 300 mg o.d. o 150 mg b.i.d. J Chemother 1990; 2 (Suppl 2): 427-429.
   Google Scholar
• Hollender LF, Bahnini J, De Manzini N, et al. A mul-ticentric study of netilmicin once daily versus thrice daily in pateints with appendicitis and other abdominal infections. J Antimicrob Chemother 1989; 23: 773–783.
   PubMed Web of Science ®Google Scholar
• Velluti G, Covi M, Capelli O, et al. Netilmicin given as a single daily dose in the treatment of lower respiratory tract and other systemic infections. J Drug Develop 1988; 1 (Suppl 3): 137–143.
   Google Scholar
• De Vries PJ, Verkooyen RP, Leguit P, Verbrug HA. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis 1990; 9: 161–168.
   PubMed Web of Science ®Google Scholar
• Novelli A, Mazzei T, Fallani S, Cassetta MI, Periti E, Periti P. Clinical pharmacokinetics and tissue penetration of netilmicin given once versus twice daily. J Chemother 1991; 3 (Suppl 4): 229–232.
   Google Scholar
• Mailer R, Isaksson B, Nilsson L, Sören L. A study of amikacin given once versus twice daily in serious infections. J Antimicrob Chemother 1988; 22: 75–79.
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Yiallouros K, Petrikkos G, et al. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic Gram-nega-tive infections. J Antimicrob Chemother 1991; 27 (Suppl C): 73-79.
   Google Scholar
• Franson TR, Quebbeman EJ, Whipple J, et al. Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods. Crit Care Med 1988; 16: 840–843.
   PubMed Web of Science ®Google Scholar
• Perkins MW. Failure of a nomogram to achieve target aminoglycoside concentrations. Br J Clin Pharmacol 1990; 29: 495–496.
   PubMed Web of Science ®Google Scholar
• Reed RL, Wu H, Miller-Crotchett P, Crotchett J, Fischer RP. Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. J Trauma 1989; 29: 1462–1470.
   PubMedGoogle Scholar
• Kapusnik JE, Sande MA. Challenging conventional aminoglycoside dosing regimens. Am J Med 1986; 80 (Suppl 6B): 179-181.
   Google Scholar
• Bodey GP, Rodriguez V, Valdivieso M, Feld R. Amikacin for treatment of infections in patients with malig-nant diseases. J Infect Dis 1976; 134 (Suppl): S421-S426.
   Google Scholar
• Martino P, Girmenia C, Raccah R, Micozzi A, Cimino G, Mandelli F. Ceftriaxone and amikacin as single daily dose in the empiric therapy for febrile episodes in neutropenic patients. Haematologica 1990; 75: 69–74.
   PubMed Web of Science ®Google Scholar
• Leoni F, Cioffi S, Pascarella A, Fanci R, Caporale R, Rossi Ferrini PL. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients. Chemotherapy 1993; 39: 147–152
   PubMed Web of Science ®Google Scholar
• Carlstedt BC, Uaamnuichai M, Bart Day R, Bowman L, Craig Bater D. Aminoglycoside dosing in pediatric pa-tients. Therap Drug Monit 1989; 11: 38–43.
   PubMed Web of Science ®Google Scholar
• Kafetzis DA, Sianidou L, Vlachos E, et al. Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe Gram-negative infections. J Antimicrob Chemother 1991; 27 (Suppl C): 105-112.
   Google Scholar
• Trujillo H, Robledo J, Robledo C, et al. Single daily dose amikacin in paediatric patients with severe Gram-nega-tive infections. J Antimicrob Chemother 1991; 27 (Suppl C): 141-147.
   Google Scholar
• Viscoli C, Dudley M, Ferrea G, et al. Serum concen-trations and safety of single daily dosing of amikacin in chil- dren undergoing bone marrow transplantation. J Antimicrob Chemother 1991; 27 (Suppl C): 113-120.
   Google Scholar
• Heininger U, Bowing B, Stehr K, Solbach W. Aminoglykoside bei patienten mit mukoviszidose und pul-monaler exazerbation: vergleich von Einmal- und dreimal-gabe. Kiln Padiatr 1993; 205: 18–22.
   PubMed Web of Science ®Google Scholar
• Elhanan K, Siplovich L, Raz R. Gentamicin once-daily versus thrice-daily in children. J Antimicrob Chemother 1995; 35: 327–332.
   PubMed Web of Science ®Google Scholar
• Lavezo LA, Davis RL. Two- versus three-sample method for estimating gentamicin pharmacokinetic values - Report. Am J Hosp Pharm 1994; 51: 1021–1024.
   PubMedGoogle Scholar
• Uematsu T. Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evalua-tion of Bayesian prediction method for approximation of individual clearance of drug. Int J Clin Pharmacol Therapy Toxicol 1993; 31: 606–610.
   PubMed Web of Science ®Google Scholar
• Matsumoto F. Routes and dosages administration. In: The Aminoglycosides (Ueda Y, Ed). Nakodo Press, Tokyo 1985: 208-214.
   Google Scholar
• Totsuka K, Shimizu K, Mitomi N, Niizato T, Araake M. Evaluation of once-daily administration of arbekacin. Experimental study and determination of pharmacokinetic propoerties in man. Jpn J Antibiot 1994; 47: 676–692.
   PubMedGoogle Scholar
• Periti P. La chemioterapia antimicrobica ed antiblasti-ca verso il 2000: risultati e prospettive. Lettura inaugurale del XVIII Congresso della Societa Italiana di Chemioterapia, Baveno-Stresa 9-12 maggio 1993. Giom Ital Chemioter 1993; 40: 65–83.
   Google Scholar
• Feld R, Rachlis A, Tuffnell P, et al. Empiric therapy for infections in patients with granulocytopenia: continuous vs. interrupted infusion of tobramycin plus cefamandole. Arch Inter Med 1984; 144: 1005–1010.
   PubMedGoogle Scholar
• Gibson J, Johnson L, Snowdon L, et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomized trial. Int J Hematol 1993; 58: 63–72.
   PubMed Web of Science ®Google Scholar
• Proctor L, Petty B, Thakor R, et al. A study of the potential vestibulotoxic effects of once daily versus thrice daily administration of tobramycin. Laryngoscope 1987; 97: 1443–1449.
   PubMed Web of Science ®Google Scholar
• Angelov A, Barrientos G, Gutensohn G, et al. Die tagliche einmaldosis von gentamicin bei der behandlung von hamwegsinfektionen. Munch Med Woch 1980; 122: 212–214.
   Google Scholar
• Nordstrom L, Cronberg S, Ringberg H, Tjemstrom O, Walder M. Prospective, comparative, randomized clinical study of aminoglycosides given once a day versus three times a day in severe infections. In: Ishigami J, Ed. Recent Advances in Chemotherapy. Tokyo, University of Tokyo Press, 1985: 2653-2654.
   Google Scholar
• Hansen M, Achen F, Carstensen C, et al. Once versus thrice daily dosing of netilmicin in febrile immunocompro-mised patients: a randomized, controlled study of efficacy and safety. J Drug Dev 1988; 1: 119–124.
   Google Scholar
• Cohen B, Saginur R, Clecner B, et al. Double-blind comparative trial of once-daily versus twice-daily netilmicin therapy in severe acute urinary tract infections. Curr Ther Res 1985; 38: 880–884.
   Web of Science ®Google Scholar
• Fan ST, Lau WY, Teoh-Chan CH, Lau KF, Mauracher EH. Once daily administration of netilmicin com-pared with thrice daily, both in combination with metronida-zole, in gangrenous and perforated appendicitis. J Antimicrob Chemother 1988; 22: 69–74.
   PubMed Web of Science ®Google Scholar
• Tulkens PM, Clerkx-Braun F, Donnez J, et al. Safety and efficacy of aminoglycosides once-a-day: experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory disease. J Drug Dev 1988; 1 (Suppl 3): 71–82.
   Google Scholar
• Sturm AW. Netilmicin in the treatment of gram-nega-tive bacteremia: single daily dose versus multiple daily dosage. J Infect Dis 1989; 159: 931–937.
   PubMed Web of Science ®Google Scholar
• Mauracher EH, Lau W, Kartowisastro H, et al. Comparison of once-daily and thrice-daily netilmicin regi-mens in serious systemic infections: a multicenter study in six Asian countries. Clin Ther 1989; 11: 604–613.
   PubMed Web of Science ®Google Scholar
• Van der Auwera P, Meunier F, Ibrahim S, et al. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother 1991; 35: 640–647.
   PubMed Web of Science ®Google Scholar
• Periti P, Mazzei T, Novelli A, Rizzo M. Efficacy and safety of once-daily versus twice-daily administration of netilmicin in patients with urinary tract infections. J Chemother 1991; Suppl 4: 369-371.
   Google Scholar
• Vigan6 A, Principi N, Brivio L, et al. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treat-ment of gram negative pyelonephritis in children. Antimicrob Agents Chemother 1992; 36: 1499-1503.
   Google Scholar
• Maller R, Emandelsson BM, Isaksson B, Nilsson L. Amikacin once daily: a new dosing regimen based on drug pharmacokinetics. Scand J Infect Dis 1990; 22: 575–579.
   PubMed Web of Science ®Google Scholar
• Maller R, Ahme H, Eilard T, et al. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. J Antimicrob Chemother 1991; 27 (Suppl C): 121-128.
   Google Scholar
• Vanhaeverbeek M, Siska G, Douchamps J, et al. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe Gram-negative infec-tions in the elderly. Int J Clin Pharmacol Ther Toxicol 1993; 31: 153–156.
   PubMed Web of Science ®Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584–593.
   Google Scholar
• Ibrahim S, Derde MP, Kaufman L, et al. Safety, phar-macokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suf-fering from pelvic inflammatory disease. Ren Fail 1990; 12 (3): 199–203.
   PubMed Web of Science ®Google Scholar
• Noone P, Pattison JR, Garfield Danies D. The effec-tive use of gentamicin in life-threatening sepsis. Postgrad Med J 1974; 50 (Suppl 7): 9–16.
   PubMedGoogle Scholar
• Cometta A, Zinner S, De Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39 (2): 445–452.
   PubMed Web of Science ®Google Scholar
• Barclay ML, Begg EJ, Hickling KG. What is the evi-dence for once-daily aminoglycoside therapy? Clin Pharmacokinet 1992; 27 (1): 32–48.
   Web of Science ®Google Scholar
• Lerner SA, Schmitt BA, Seligsohn R, et al. Comparative study of ototoxicity and nephrotoxicity in pa-tients randomly assigned to treatment with amikacin or gen-tamicin. Am J Med 1986; 80 (Suppl 6B): 98-104.
   Google Scholar
• Moore RD, Smith CR, Lietman PS. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med 1986; 80: 1093–1097.
   PubMed Web of Science ®Google Scholar
• Bennett WM, Hartnett MN, Gilbert DN, et al. Effect of sodium intake on gentamicin nephrotoxicity in the rat. Proc Soc Exp Biol Med 1976; 151: 736–738.
   PubMed Web of Science ®Google Scholar
• Wood CA, Norton SJ, Kohlhepp PW, et al. Vancomycin enhancement of experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother 1986; 30: 20–24.
   PubMed Web of Science ®Google Scholar
• Gilbert DN, Bennett WM. Progress in the elucidation of aminoglycoside nephrotoxodty. Contemp Issues Infect Dis 1984; 1: 121–152.
   Google Scholar
• De Broe ME, Guiliano RA, Verpooten GA. Choice of drug and dosage regimen: two important risk factors for aminoglycoside nephrotoxicity. Am J Med 1986; 80 (Suppl 6B): 115-118.
   Google Scholar
• Gailiunas P, Dominguez-Moreno M, Lazarus JM, et al. Vestibular toxicity of gentamicin: incidence in patients receiv-ing long-term hemodialysis therapy. Arch Intern Med 1978; 138: 1621–1624.
   PubMedGoogle Scholar
• Crass RE. Gentamicin-induced ototoxicity in a careful-ly monitored renal failure patient. Am J Hosp Pharm 1981; 38: 540–545.
   PubMedGoogle Scholar
• Neu HC, Benush CL. Ototoxicity of tobramycin: a clinical overview. J Infect Dis 1976; 134 (Suppl): S206-S218.
   Google Scholar
• Beaubien AR, Desjardin S, Ormsby E, et al. Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels. Am J Otolaryngol 1989; 10: 234–243.
   PubMed Web of Science ®Google Scholar
• Bertino JS, Booker LA, Franck PA, Jenkins PL, Franc KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167: 173–179.
   PubMed Web of Science ®Google Scholar